Your browser doesn't support javascript.
loading
Measures to prevent and treat Nipah virus disease: research priorities for 2024-29.
Moore, Kristine A; Mehr, Angela J; Ostrowsky, Julia T; Ulrich, Angela K; Moua, Nicolina M; Fay, Petra C; Hart, Peter J; Golding, Josephine P; Benassi, Virginia; Preziosi, Marie-Pierre; Broder, Christopher C; de Wit, Emmie; Formenty, Pierre B H; Freiberg, Alexander N; Gurley, Emily S; Halpin, Kim; Luby, Stephen P; Mazzola, Laura T; Montgomery, Joel M; Spiropoulou, Christina F; Mourya, Devendra T; Parveen, Shahana; Rahman, Mahmudur; Roth, Cathy; Wang, Lin-Fa; Osterholm, Michael T.
  • Moore KA; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA. Electronic address: kamoore@umn.edu.
  • Mehr AJ; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.
  • Ostrowsky JT; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.
  • Ulrich AK; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.
  • Moua NM; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.
  • Fay PC; Wellcome Trust, London, UK.
  • Hart PJ; Wellcome Trust, London, UK.
  • Golding JP; Wellcome Trust, London, UK.
  • Benassi V; World Health Organization, Geneva, Switzerland.
  • Preziosi MP; World Health Organization, Geneva, Switzerland.
  • Broder CC; Uniformed Services University, Bethesda, MD, USA.
  • de Wit E; Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • Formenty PBH; World Health Organization, Geneva, Switzerland.
  • Freiberg AN; University of Texas Medical Branch, Galveston, TX, USA.
  • Gurley ES; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Halpin K; Commonwealth Scientific and Industrial Research Organisation, Geelong, VIC, Australia.
  • Luby SP; Stanford University, Stanford, CA, USA.
  • Mazzola LT; FIND, Geneva, Switzerland.
  • Montgomery JM; Viral Special Pathogens Branch, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Spiropoulou CF; Viral Special Pathogens Branch, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Mourya DT; National Institute of Virology, Pune, India.
  • Parveen S; ICDDR,B, Dhaka, Bangladesh.
  • Rahman M; Eastern Mediterranean Public Health Network, Bangladesh Country Office, Dhaka, Bangladesh.
  • Roth C; UK Foreign, Commonwealth and Development Office, London, UK.
  • Wang LF; Duke-NUS Medical School, Singapore.
  • Osterholm MT; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.
Lancet Infect Dis ; 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38964362
ABSTRACT
Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100% in recognised outbreaks. No treatments or licensed vaccines are currently available for the prevention and control of Nipah virus infection. In 2019, WHO published an advanced draft of a research and development roadmap for accelerating development of medical countermeasures, including diagnostics, therapeutics, and vaccines, to enable effective and timely emergency response to Nipah virus outbreaks. This Personal View provides an update to the WHO roadmap by defining current research priorities for development of Nipah virus medical countermeasures, based primarily on literature published in the last 5 years and consensus opinion of 15 subject matter experts with broad experience in development of medical countermeasures for Nipah virus or experience in the epidemiology, ecology, or public health control of outbreaks of Nipah virus. The research priorities are organised into four main sections cross-cutting issues (for those that apply to more than one category of medical countermeasures), diagnostics, therapeutics, and vaccines. The strategic goals and milestones identified in each section focus on key achievements that are needed over the next 6 years to ensure that the necessary tools are available for rapid response to future outbreaks of Nipah virus or related henipaviruses.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article